Loading
A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Imvax, active and no longer recruiting.
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma is a phase 2 interventional study registered as NCT04485949 by Imvax, with 99 participants enrolled, started 2023-03-20 and due to reach its primary completion in 2027-01. Interventions recorded: IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy and SOC: Temozolomide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/